Cardiomyopathy

May 2026 saw substantial FDA decisions, major trial results, guideline updates, and more.

FDA accepted a priority review sNDA for mavacamten in adolescents with symptomatic obstructive hypertrophic cardiomyopathy.

The FDA granted Fast Track Designation to coramitug, an investigational anti-TTR antibody designed to clear existing amyloid deposits in ATTR cardiomyopathy.

Catch up on major trial results, groundbreaking guideline updates, and more.

Catch up on data from some of the most impactful trials presented at the American College of Cardiology 2026.

New information from the phase 3 SCOUT-HCM trial indicate the benefits of mavacamten may extend to adolescents as well as adults.

Catch up with major FDA decisions, key guidelines updates, and more.

Bristol Myers Squibb has reported positive results from the ongoing SCOUT-HCM trial, demonstrating mavacamten’s efficacy in reducing Valsalva LVOT.

The Q4 recap for cardiology spotlights major FDA decisions, key clinical trial updates, and more.

Catch up with major FDA decisions, critical conference news, and more.

The approval is based on phase 3 SEQUOIA-HCM clinical trial. The full US Prescribing Information includes a Boxed Warning for the risk of heart failure.

Catch up with major FDA decisions, critical conference news, and more.

Acoramidis also increased serum transthyretin in patients with wild-type ATTR-CM or the pathogenic variant ATTRv-CM.

Catch up with groundbreaking FDA decisions, exciting new GLP-1 news, and more.

A recent study from Duke University spotlighted papSCAR’s substantial association with both cardiovascular mortality and arrhythmia.

Desai details recent advancements in medicine and invasive treatments while reminding clinicians of what can still be done to protect patients.

The Q3 recap for cardiology spotlights major FDA decisions, new heart failure and hypertension guidelines, and top trial results and research.

Read about groundbreaking FDA decisions, exciting new heart failure research, and more.

This set of interviews collects perspectives from 11 leading clinicians in the heart failure field, cataloguing the biggest news from 2025.

Aficamten shows superior exercise capacity improvements over metoprolol for patients with oHCM.

New 96-week data reveals aficamten's significant benefits for patients with nonobstructive hypertrophic cardiomyopathy.

Acoramidis significantly lowers cardiovascular event risk in ATTR-CM, emphasizing the need for early diagnosis & treatment.

Arora discusses the results of Bristol Myers Squibb’s observational study and the implications it has for the study of obstructive HCM and cardiology at large.

A recap 8 clinical trials in cardiovascular care to know from the European Society of Cardiology Congress 2025.

Aficamten shows significant benefits over metoprolol in treating symptomatic obstructive HCM, potentially changing first-line therapy approaches.